VERU Stock Overview
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS).
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Veru Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.53 |
| 52 Week High | US$1.92 |
| 52 Week Low | US$0.36 |
| Beta | -0.20 |
| 1 Month Change | 163.79% |
| 3 Month Change | 267.97% |
| 1 Year Change | 47.12% |
| 3 Year Change | -83.17% |
| 5 Year Change | 6.99% |
| Change since IPO | -76.91% |
Recent News & Updates
Recent updates
The Price Is Right For Veru Inc. (NASDAQ:VERU) Even After Diving 52%
Jan 09
Revenue Downgrade: Here's What Analysts Forecast For Veru Inc. (NASDAQ:VERU)
Aug 16Veru Inc.'s (NASDAQ:VERU) Stock Retreats 38% But Revenues Haven't Escaped The Attention Of Investors
Apr 17Veru Inc.'s (NASDAQ:VERU) Intrinsic Value Is Potentially 99% Above Its Share Price
Feb 14Veru (NASDAQ:VERU) Has Debt But No Earnings; Should You Worry?
Jan 13Analysts Just Shaved Their Veru Inc. (NASDAQ:VERU) Forecasts Dramatically
Nov 13Veru Inc.: Safer Bet Is To Wait For The AdComm Verdict
Oct 17Is Veru (NASDAQ:VERU) Weighed On By Its Debt Load?
Sep 26Veru FDA AdCom meeting for COVID-19 therapy postponed
Sep 19Veru: A Good Combination Of A Stable Business And Growth Opportunities
Sep 13Veru surges 11% as FDA sets AdCom meeting to review COVID-19 therapy
Sep 07Veru sheds 13% to end rally as director sells shares
Aug 18Veru Q3 2022 Earnings Preview
Aug 10Veru updated analysis on COVID treatment sabizabulin will lead to EUA - Oppenheimer
Aug 03Veru eligible for expedited review in U.K. for COVID-19 therapy
Jul 25Veru: The Signs Seem To Point To An EUA For Sabizabulin
Jul 13Veru phase 3 results of sabizabulin for COVID-19 published in NEJM
Jul 06Veru: On Right Track For FDA EUA Submission
May 27Is Veru (NASDAQ:VERU) Using Debt Sensibly?
May 25Veru: Where Big Pharma Failed To Tread
May 17Veru: The Russian/Ukraine Conflict May Pose Challenges
Mar 03Shareholder Returns
| VERU | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 48.5% | -5.2% | -3.1% |
| 1Y | 47.1% | -34.8% | 20.9% |
Return vs Industry: VERU exceeded the US Personal Products industry which returned -34.1% over the past year.
Return vs Market: VERU exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| VERU volatility | |
|---|---|
| VERU Average Weekly Movement | 19.4% |
| Personal Products Industry Average Movement | 8.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VERU's share price has been volatile over the past 3 months.
Volatility Over Time: VERU's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1971 | 189 | Mitch Steiner | verupharma.com |
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company’s development program includes enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, a selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection on oxygen support who are at high risk for viral induced ARDS and death.
Veru Inc. Fundamentals Summary
| VERU fundamental statistics | |
|---|---|
| Market cap | US$222.50m |
| Earnings (TTM) | -US$62.72m |
| Revenue (TTM) | US$15.93m |
14.1x
P/S Ratio-3.6x
P/E RatioIs VERU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VERU income statement (TTM) | |
|---|---|
| Revenue | US$15.93m |
| Cost of Revenue | US$7.92m |
| Gross Profit | US$8.01m |
| Other Expenses | US$70.73m |
| Earnings | -US$62.72m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.43 |
| Gross Margin | 50.31% |
| Net Profit Margin | -393.72% |
| Debt/Equity Ratio | 19.0% |
How did VERU perform over the long term?
See historical performance and comparison